Additionally, the proposed involvement of DNA-PKcs in the RSR13–15 also suggests that DNA-PK inhibitors could be useful in targeting tumours with high levels of replication stress, either as a single agent or in combination with other agents that modulate the RSR, such as ATR inhibitor AZD6738. Here, ATR is linked to neoplasm.